Trial Profile
Clinical outcomes of patients with HER2 gene-amplified metastatic breast cancer treated with first line herceptin [trastuzumab] in combination with a taxane: A phase IV, prospective, community based study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Taxanes
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Genentech
- 28 Feb 2018 Status changed from active, no longer recruiting to completed.
- 27 Jan 2006 New trial record.